Opana
(Oxymorphone)Phase 3Small molecule
Opana is one of 102 small molecule programs targeting Neuropathic Pain. It is currently in Phase 3.
3
Indications
10
Total Trials
0
Active Trials
101
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
224 competitors in Nausea and Vomiting
#DrugCompanyPhaseTrials
1Opana
GGrupo Espanol de Tumores Neuroendocrinos
Phase 3
Aloxi
AAvyxa
Preclinical
Alfenta
Alnylam PharmaceuticalsPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Phenergan
BBassett Healthcare
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety3 trials
TED2 trials
Nausea and vomiting1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
OPANA
NDA NDA011707
Jan 1, 1982
NUMORPHAN
NDA NDA011738
Jun 22, 2006
OPANA ER
NDA NDA021610
Jun 22, 2006
OPANA
NDA NDA021611
Dec 9, 2011
OPANA ER
NDA NDA201655
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxymorphone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Opana. U.S. Food & Drug Administration.
- [6]